Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells

Citations Over TimeTop 10% of 2014 papers

Abstract

DNA methyltransferases (DNMTs) are important enzymes involved in epigenetic control of gene expression and represent valuable targets in cancer chemotherapy. A number of nucleoside DNMT inhibitors (DNMTi) have been studied in cancer, including in cancer stem cells, and two of them (azacytidine and decitabine) have been approved for treatment of myelodysplastic syndromes. However, only a few non-nucleoside DNMTi have been identified so far, and even fewer have been validated in cancer. Through a process of hit-to-lead optimization, we report here the discovery of compound 5 as a potent non-nucleoside DNMTi that is also selective toward other AdoMet-dependent protein methyltransferases. Compound 5 was potent at single-digit micromolar concentrations against a panel of cancer cells and was less toxic in peripheral blood mononuclear cells than two other compounds tested. In mouse medulloblastoma stem cells, 5 inhibited cell growth, whereas related compound 2 showed high cell differentiation. To the best of our knowledge, 2 and 5 are the first non-nucleoside DNMTi tested in a cancer stem cell line.

Related Papers

• → Concise Drug Review: Azacitidine and Decitabine(2013)291 cited
• → Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine(2008)102 cited
• → Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis(2021)17 cited
• → The euphoria of hypomethylating agents in MDS and AML: Is it justified?(2013)8 cited
• → Improved Responses with Azacitidine Compared to Decitabine in Patients with Acute Myeloid Leukemia in Patients ≥70 with Poor-Risk Cytogenetics(2017)5 cited